

1647

Please type a plus sign (+) inside this box → ☐

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

SEP 04 2003
U.S. PATENT & TRADEMARK OFFICE

| | | | |
|---|----|------------------------|-------------------------|
| TRANSMITTAL FORM (to be used for all correspondence after initial filing) | | Application Number | 09/580,018 |
| | | Filing Date | May 26, 2000 |
| | | First Named Inventor | Schenk, Dale B. |
| | | Group Art Unit | 1647 |
| | | Examiner Name | Nichols, Christopher J. |
| Total Number of Pages in This Submission | 15 | Attorney Docket Number | 15270J-004760US |

| ENCLOSURES (check all that apply) | | |
|--|--|---|
| <input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Supplemental Information Disclosure Statement (14 pp) 17 volumes of references (nos. 1-339) <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) | <input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 1. Return Postcard (1pg) |
| Remarks: The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430. | | * Note: References not included in total number of pages. |

| SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT | |
|--|--|
| Firm and Individual name | Townsend and Townsend and Crew LLP Rosemarie L. Celli Reg. No. 42,397 |
| Signature | |
| Date | August 22, 2003 |

| CERTIFICATE OF MAILING | |
|--|---------------|
| I hereby certify that this correspondence is being delivered, VIA HAND DELIVERY to: US Patent and Trademark Office, 2011 South Clark Place, Customer Window, Crystal Plaza Two, Lobby, Room 1B03, Arlington, Virginia 22202 on this date: | |
| Typed or printed name | Heather Savia |
| Signature | |
| Date | 9/4/03 |

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 60024668 v1

I hereby certify that this correspondence is being delivered by
Hand Delivery to:

US Patent and Trademark Office
2011 South Clark Place
Customer Window
Crystal Plaza Two, Lobby, Room 1B03
Arlington, Virginia 22202



PATENT
Attorney Docket No.: 15270J-004760US
Client Reference No.: 209-US-CIP8B

On 9/4/03

By: [Signature]
PRIOR ART SEARCHES

Application No.: 09/580,018
Filed: May 26, 2000
Examiner: Christopher J. Nichols

Confirmation No.: 9973

TC/AU: 1647
Customer No.: 20350

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants filed Information Disclosure Statements, along with their respective PTO/SB/08A & 08B forms, on November 3, 2000, January 8, 2001, January 8, 2002, and February 18, 2003 for the above-captioned application. In accordance with 37 C.F.R. § 1.98(d), Applicants relied on references previously submitted for U.S. Application No. 09/322,289 or U.S. Application No. 09/201,289. The above-captioned application no longer claims priority under 35 U.S.C. § 120 to U.S. Application Nos. 09/322,289 and No. 09/201,289. Consequently, Applicants can no longer rely on § 1.98(d) and, therefore, submit copies of the references cited by the above-mentioned Information Disclosure Statements herewith.

The following table lists the previously cited references.

| | | | | |
|---|-----------|--|------------|----------------|
| 1 | 6,057,367 | | 05-02-2000 | Stamler et al. |
| 2 | 5,958,883 | | 09-28-1999 | Snow |
| 3 | 5,955,317 | | 09-21-1999 | Suzuki et al. |
| 4 | 5,955,079 | | 09-21-1999 | Mond et al. |



| | | | | | |
|----|----|-----------|----|------------|-------------------|
| 5 | | 5,877,399 | | 03-02-1999 | Hsiao et al. |
| 6 | | 5,869,093 | | 02-09-1999 | Weiner et al. |
| 7 | | 5,869,054 | | 02-09-1999 | Weiner et al. |
| 8 | | 5,854,204 | | 12-29-1998 | Findeis et al. |
| 9 | | 5,851,996 | | 12-22-1998 | Kline |
| 10 | | 5,849,298 | | 12-15-1998 | Weiner et al. |
| 11 | | 5,837,473 | | 11-17-1998 | Maggio et al. |
| 12 | | 5,786,180 | | 07-28-1998 | Konig et al. |
| 13 | | 5,753,624 | | 05-19-1998 | McMichael et al. |
| 14 | | 5,750,349 | | 05-12-1998 | Suzuki et al. |
| 15 | | 5,733,547 | | 03-31-1998 | Weiner et al. |
| 16 | | 5,688,651 | | 11-18-1997 | Solomon |
| 17 | | 5,679,348 | | 10-21-1997 | Nesburn et al. |
| 18 | | 5,645,820 | | 07-08-1997 | Hafler et al. |
| 19 | | 5,641,474 | | 06-24-1997 | Hafler et al. |
| 20 | | 5,641,473 | | 06-24-1997 | Hafler et al. |
| 21 | | 5,612,486 | | 03-18-1997 | McConlogue et al. |
| 22 | | 5,605,811 | | 02-25-1997 | Seubert et al. |
| 23 | | 5,585,100 | | 12-17-1996 | Mond et al. |
| 24 | | 5,571,500 | | 11-05-1996 | Hafler et al. |
| 25 | | 5,571,499 | | 11-05-1996 | Hafler et al. |
| 26 | | 5,434,170 | | 07-18-1995 | Andrulis, Jr. |
| 27 | | 5,387,742 | | 02-07-1995 | Cordell |
| 28 | | 5,231,000 | | 07-27-1993 | Majocha et al. |
| 29 | | 5,220,013 | | 06-15-1993 | Ponte et al. |
| 30 | | 5,208,036 | | 05-04-1993 | Eppstein et al. |
| 31 | | 5,192,753 | | 03-09-1993 | McGeer et al. |
| 32 | | 5,187,153 | | 02-16-1993 | Cordell et al. |
| 33 | | 5,057,540 | | 10-15-1991 | Kensil et al. |
| 34 | | 4,666,829 | | 05-19-1987 | Glennner et al. |
| 35 | EP | 911 036 | A2 | 04-28-1999 | |
| 36 | EP | 868 918 | A2 | 10-07-1998 | |
| 37 | EP | 863 211 | A1 | 09-09-1998 | |
| 38 | EP | 845 270 | A1 | 06-03-1998 | |
| 39 | EP | 782 859 | A1 | 07-09-1997 | |
| 40 | EP | 683 234 | A1 | 11-22-1995 | |
| 41 | EP | 666 080 | A1 | 08-09-1995 | |
| 42 | EP | 652 962 | B1 | 12-16-1998 | |
| 43 | EP | 639 081 | B1 | 11-03-1999 | |
| 44 | EP | 613 007 | A2 | 08-31-1994 | |
| 45 | EP | 594 607 | B1 | 08-27-1997 | |
| 46 | EP | 561 087 | B1 | 08-04-1999 | |
| 47 | EP | 526 511 | B1 | 05-28-1997 | |
| 48 | EP | 506 785 | B1 | 03-15-2000 | |
| 49 | EP | 451 700 | A1 | 10-16-1991 | |
| 50 | EP | 440 619 | B1 | 01-24-1996 | |
| 51 | EP | 359 783 | B1 | 11-29-1995 | |
| 52 | EP | 276 723 | B1 | 12-08-1993 | |
| 53 | WO | 99/60024 | A1 | 11-25-1999 | |
| 54 | WO | 99/60021 | A2 | 11-15-1999 | |
| 55 | WO | 99/58564 | A1 | 11-18-1999 | |
| 56 | WO | 99/06066 | A2 | 02-11-1999 | |
| 57 | WO | 99/27949 | A1 | 06-10-1999 | |

| | | | | | |
|-----|--|-----------|----|------------|--|
| 58 | WO | 99/27944 | A1 | 06-10-1999 | |
| 59 | WO | 99/27911 | A1 | 06-10-1999 | |
| 60 | WO | 98/44955 | A1 | 10-15-1998 | |
| 61 | WO | 98/07850 | A2 | 02-26-1998 | |
| 62 | WO | 97/17613 | A1 | 05-15-1997 | |
| 63 | WO | 96/39176 | A1 | 12-12-1996 | |
| 64 | WO | 96/25435 | A1 | 08-22-1996 | |
| 65 | WO | 96/18900 | A1 | 06-20-1996 | |
| 66 | WO | 95/31996 | A1 | 11-30-1995 | |
| 67 | WO | 95/11994 | A1 | 05-04-1995 | |
| 68 | WO | 95/11311 | A1 | 04-27-1995 | |
| 69 | WO | 95/05853 | A1 | 03-02-1995 | |
| 70 | WO | 95/04151 | A2 | 02-09-1995 | |
| 71 | WO | 94/03615 | A1 | 02-17-1994 | |
| 72 | WO | 94/01772 | A1 | 01-20-1994 | |
| 73 | WO | 93/21950 | A1 | 11-11-1993 | |
| 74 | WO | 93/16724 | A1 | 09-02-1993 | |
| 75 | WO | 93/15760 | A1 | 08-19-1993 | |
| 76 | WO | 93/14200 | A1 | 07-22-1993 | |
| 77 | WO | 93/02189 | A1 | 02-04-1993 | |
| 78 | WO | 92/13069 | A1 | 08-06-1992 | |
| 79 | WO | 92/06708 | A1 | 04-30-1992 | |
| 80 | WO | 92/06187 | A1 | 04-16-1992 | |
| 81 | WO | 91/19810 | A1 | 12-26-1991 | |
| 82 | WO | 91/16819 | A1 | 11-14-1991 | |
| 83 | WO | 91/12816 | A1 | 09-05-1991 | |
| 84 | WO | 91/08760 | A1 | 06-27-1991 | |
| 85 | WO | 90/12871 | A1 | 11-01-1990 | |
| 86 | WO | 90/12870 | A1 | 11-01-1990 | |
| 87 | WO | 89/01343 | A1 | 02-23-1989 | |
| 88 | WO | 89/06242 | A1 | 07-13-1989 | |
| 89 | WO | 89/06689 | A1 | 07-27-1989 | |
| 90 | WO | 89/03687 | A1 | 05-05-1989 | |
| 91 | WO | 88/10120 | A1 | 12-29-1988 | |
| 92 | GB | 2 220 211 | A | 01-04-1990 | |
| 93 | GB | 2 335 192 | A | 09-15-1999 | |
| 94 | ANDERSEN et al., "Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease?", <u>Neurology</u> , 45:1441-1445 (1995). | | | | |
| 95 | Associated Press, "Immune cells may promote Alzheimer's, a study finds," <u>The Boston Globe</u> (4/13/95). | | | | |
| 96 | BAUER et al., "Interleukin-6 and α -2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices," <u>FEBS Letters</u> , 285(1):111-114 (1991). | | | | |
| 97 | BLASS, "Immunologic Treatment of Alzheimer's Disease," <u>New England J. Medicine</u> , 341(22):1694 (1999). | | | | |
| 98 | BODMER et al., "Transforming Growth Factor-Beta Bound to Soluble Derivatives of the Beta Amyloid Precursor Protein of Alzheimer's Disease," <u>Biochem. Biophys. Res. Comm.</u> , 171(2):890-897 (1990). | | | | |
| 99 | BORCHELT et al., "Accelerated Amyloid Deposition in the Brains of Transgenic Mice Coexpressing Mutant Presenilin 1 and Amyloid Precursor Proteins," <u>Neuron</u> , 19: 939-945 (1997). | | | | |
| 100 | BORIS-LAWRIE et al., "Recent advances in retrovirus vector technology," <u>Cur. Opin. Genetic Develop.</u> , 3: 102-109 (1993). | | | | |

| | |
|-----|--|
| 101 | BRICE et al., "Absence of the amyloid precursor protein gene mutation (APP717 : Val->Ile) in 85 cases of early onset Alzheimer's disease," <u>J. Neurology, Neurosurg. Psychiatry</u> , 56:112-115 (1993). |
| 102 | CHAO et al., "Transforming Growth Factor- β Protects human Neurons Against β -Amyloid-Induced Injury," <u>Soc. Neurosci. Abstracts</u> , 19:513-7 (1993). |
| 103 | DUFF et al., "Mouse model made," <u>Nature</u> , 373: 476-477 (1995). |
| 104 | ELIZAN et al., "Antineurofilament antibodies in a postencephalitic and idiopathic Parkinson's disease," <u>J. Neurol. Sciences</u> , 59:341-347 (1983). |
| 105 | FELSENSTEIN et al., "Processing of the β -amyloid precursor protein carrying the familial, Dutch-type, and a novel recombinant C-terminal mutation," <u>Neuroscience Letters</u> , 152:185-189 (1993). |
| 106 | FINCH et al., "Evolutionary Perspectives on Amyloid and Inflammatory Features of Alzheimer Disease," <u>Neurobiology of Aging</u> , 17(5):809-815 (1996). |
| 107 | FISHER et al., "Expression of the amyloid precursor protein gene in mouse oocytes and embryos," <u>PNAS</u> , 88:1779-1782 (1991). |
| 108 | FLANDERS et al., "Altered expression of transforming growth factor- β in Alzheimer's disease," <u>Neurology</u> , 45:1561-1569 (1995). |
| 109 | GAMES et al., "Alzheimer-type neuropathology in transgenic mice overexpressing V717F β -amyloid precursor protein," <u>Nature</u> , 373(6514): 523-527 (1995). |
| 110 | GANDY et al., "Amyloidogenesis in Alzheimer's disease: some possible therapeutic opportunities," <u>TIPS</u> , 13:108-113 (1992). |
| 111 | GASKIN et al., "Human antibodies reactive with beta-amyloid protein in Alzheimer's disease," <u>J. Exp. Med.</u> , 177:1181-1186 (1993). |
| 112 | GLENN et al., "Skin immunization made possible by cholera toxin," <u>Nature</u> , 391: 851 (1998). |
| 113 | GLENNER et al., "Alzheimer's Disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein," <u>Biochemical and Biophysical Research Communications</u> , 120(3): 885-890 (1994). |
| 114 | GLENNER et al., "Alzheimer's Disease and Downs Syndrome: Sharing of A Unique Cerebrovascular Amyloid Fibril Protein," <u>Biochemical and Biophysical Research Communications</u> , 122(3): 1131-1135 (1984). |
| 115 | GOATE et al., "Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease," <u>Nature</u> , 349:704-706 (1991). |
| 116 | GOZES et al., "Neuroprotective strategy for Alzheimer disease: Intranasal administration of a fatty neuropeptide," <u>PNAS USA</u> , 93:427-432 (1996). |
| 117 | GUPTA et al., "Differences in the immunogenicity of native and formalized cross reacting material (CRM197) of diphtheria toxin in mice and guinea pigs and their implications on the development and control of diphtheria vaccine based on CRMs," <u>Vaccine</u> , 15(12/13): 1341-1343 (1997). |
| 118 | HAGA et al., "Synthetic Alzheimer amyloid β /A4 peptides enhance production of complement C3 component by cultured microglial cells," <u>Brain Research</u> , 601:88-94 (1993). |
| 119 | HANES et al., "New advances in microsphere-based single-dose vaccines," <u>Advanced Drug Delivery Reviews</u> , 28: 97-119 (1997). |
| 120 | HARDY, "Amyloid, the presenilins and Alzheimer's disease," <u>TINS</u> , 20(4): 154-159 (1997). |
| 121 | HARDY, John, "New Insights into the Genetics of Alzheimer's Disease," <u>Annals of Med.</u> , 28:255-258 (1996). |
| 122 | HSIAO et al., "Correlative Memory Deficits, A β Elevation, and Amyloid Plaques in Transgenic Mice," <u>Science</u> , 274: 99-102 (1996). |

| | |
|-----|--|
| 123 | HUBERMAN et al., "Correlation of cytokine secretion by mononuclear cells of Alzheimer's patients and their disease stage," <u>J. Neuroimmunology</u> , 52:147-152 (1994). |
| 124 | HYMAN et al., "Molecular Epidemiology of Alzheimer's Disease," <u>N. E. J. Medicine</u> , 333(19):1283-1284 (1995). |
| 125 | ITAGAKI et al., "Relationship of microglia and astrocytes to amyloid deposits of Alzheimer's disease," <u>J. Neuroimmunology</u> , 24:173-182 (1989). |
| 126 | JANSEN et al., "Immunotoxins: Hybrid Molecules Combining High Specificity and Potent Cytotoxicity," <u>Immun. Rev.</u> , 62: 185-216 (1982). |
| 127 | KALARIA, R. N., "Serum amyloid P and related molecules associated with the acute-phase response in Alzheimer's disease," <u>Res. Immunology</u> , 143:637-641 (1992). |
| 128 | KAWABATA et al., "Amyloid plaques, neurofibrillary tangles and neuronal loss in brains of transgenic mice overexpressing a C-terminal fragment of human amyloid precursor protein," <u>Nature</u> , 354:476-478 (1991). |
| 129 | LAMPERT-ETCHELLS et al., "Regional Localization of Cells Containing Complement C1q and C4 mRNAs in the Frontal Cortex During Alzheimer's Disease," <u>Neurodegeneration</u> , 2:111-121 (1993). |
| 130 | LANGER, "New Methods of Drug Delivery," <u>Science</u> , 249: 1527-1532 (1990). |
| 131 | LANNFELT et al., "Alzheimer's disease: molecular genetics and transgenic animal models," <u>Behavioural Brain Res.</u> , 57:207-213 (1993). |
| 132 | LEMERE et al., "Mucosal Administration of A β Peptide Decreases Cerebral Amyloid Burden In Pd-App Transgenic Mice," <u>Society for Neuroscience Abstracts</u> , vol. 25, part I, Abstract 519.6, 29th Annual Meeting, (October 23-28, 1999). |
| 133 | LIVINGSTON et al., "The Hepatitis B Virus-Specific CTL Responses Induced in Humans by Lipopeptide Vaccination Are Comparable to Those Elicited by Acute Viral Infection," <u>J. Immunol.</u> , 159: 1383-1392 (1997). |
| 134 | LOPEZ et al., "Serum auto-antibodies in Alzheimer's disease," <u>Acta. Neurol. Scand.</u> , 84:441-444 (1991). |
| 135 | MCGEE et al., "The encapsulation of a model protein in poly (D, L lactide-co-glycolide) microparticles of various sizes: an evaluation of process reproducibility," <u>J. Micro. Encap.</u> , 14(2): 197-210 (1997). |
| 136 | MEDA et al., "Activation of microglial cells by β -amyloid protein and interferon- γ ," <u>Nature</u> , 374:647-650 (1995). |
| 137 | MILLER et al., "Antigen-driven Bystander Suppression after Oral Administration of Antigens," <u>J. Exp. Med.</u> , 174:791-798 (1991). |
| 138 | NATHANSON et al., "Bovine Spongiform Encephalopathy (BSE): Causes and Consequences of a Common Source Epidemic," <u>Am. J. Epidemiol.</u> , 145(11): 959-969 (June 1, 1997). |
| 139 | New York Times National, "Anti-Inflammatory Drugs May Impede Alzheimer's," (2/20/94). |
| 140 | PARESCIE et al., "Microglial cells influence aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor," <u>Neuron</u> , 17:553-565 (September 1996). |
| 141 | PAUL et al., "Transdermal immunization with large proteins by means of ultradeformable drug carriers," <u>Eur. J. Immunol.</u> , 25: 3521-3524 (1995). |
| 142 | PRIEELS et al., "Synergistic adjuvants for vaccines," <u>Chemical Abstracts</u> , 120(8): pg. 652, column 1, abstract 86406t (1994). |
| 143 | QUON et al., "Formation of β -Amyloid protein deposits in brains of transgenic mice," <u>Nature</u> , 352:239-241 (1991). |
| 144 | RASO, V.A., Grant application # 1 R43 AG1 5746-01 (redacted version), "Immunotherapy of Alzheimer's Disease" (publication date unknown). |
| 145 | RASO, "Immunotherapy of Alzheimer's Disease," <u>Immunotherapy Weekly</u> , Abstract (April 2, 1998). |

| | |
|-----|--|
| 146 | ROGERS et al., "Complement activation by β -amyloid in Alzheimer Disease," <u>PNAS</u> , 89:1-5 (1992). |
| 147 | ROSSOR et al., "Alzheimer's Disease Families with Amyloid Precursor Protein Mutations," <u>Annals of New York Academy of Sciences</u> , 695:198-202 (1993). |
| 148 | SCHENK et al., "Immunization with amyloid- β attenuates Alzheimer-disease-like pathology in the PDAPP mouse," <u>Nature</u> , 400:173-177 (1999). |
| 149 | SELKOE, D.J., "Imaging Alzheimer's Amyloid," <u>Nat. Biotech.</u> , 18:823-824 (2000). |
| 150 | SELKOE, "Alzheimer's Disease: A Central Role for Amyloid," <u>J. Neuropathol. Exp. Neurol.</u> , 53(5): 438-447 (1994). |
| 151 | SELKOE, "Physiological production of the β -amyloid protein and the mechanism of Alzheimer's disease," <u>Trends in Neurosciences</u> , 16(10): 403-409 (1993). |
| 152 | SELKOE, Dennis J., "Amyloid Protein and Alzheimer's Disease.....," <u>Scientific American</u> , pgs. 68-78 (November, 1991). |
| 153 | SELKOE, Dennis J., "In the Beginning....," <u>Nature</u> , 354:432-433 (1991). |
| 154 | SELKOE, Dennis J., "The Molecular pathology of Alzheimer's Disease," <u>Neuron</u> , 6:487-498 (1991). |
| 155 | SELKOE, Dennis J., "Alzheimer's Disease: Genotypes, Phenotype, and Treatments," <u>Science</u> , 275:630-631 (1997). |
| 156 | SEUBERT et al., "Isolation and quantification of soluble Alzheimer's β -peptide from biological fluids," <u>Nature</u> , 359: 325-327 (1992). |
| 157 | SHIOSAKA, S., "Attempts to make models for Alzheimer's disease," <u>Neuroscience Res.</u> , 13:237-255 (1992). |
| 158 | SMITS et al., "Prion Protein and Scrapie Susceptibility," <u>Vet. Quart.</u> , 19(3): 101-105 (1997). |
| 159 | SOLOMON et al., "Disaggregation of Alzheimer β -amyloid by site-directed mAb," <u>PNAS USA</u> , 94:4109-4112 (1997). |
| 160 | SOLOMON et al., "Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer β -amyloid peptide," <u>PNAS USA</u> , 93:452-455 (1996). |
| 161 | SOLOMON, A., "Pro-Rx (Protein Therapeutics)," University of Tennessee Medical Center (publication date unknown). |
| 162 | SOLOMON, B., "New Approach Towards Fast Induction of Anti β -Amyloid Peptide Immune Response," Department of Molecular Microbiology & Biotechnology, Tel-Aviv University, Ramat Aviv, Tel-Aviv, Israel (publication date unknown). |
| 163 | STOUTE et al., "A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine Against <i>Plasmodium Falciparum Malaria</i> ," <u>N. Engl. J. Med.</u> , 336(2): 86-91 (1997). |
| 164 | STURCHLER-PIERRAT et al., "Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology," <u>PNAS</u> , 94: 13287-13292 (1997). |
| 165 | TANAKA et al., "NC-1900, an active fragment analog of arginine vasopressin, improves learning and memory deficits induced by beta-amyloid protein in rats," <u>European J. Pharmacology</u> , 352:135-142 (1998). |
| 166 | TRIEB et al., "Is Alzheimer beta amyloid precursor protein (APP) an autoantigen? Peptides corresponding to parts of the APP sequence stimulate T lymphocytes in normals, but not in patients with Alzheimer's disease," <u>Immunobiology</u> , 191(2-3):114-115 Abstract C.37, (1994). |
| 167 | VAN GOOL et al., "Concentrations of amyloid- β protein in cerebrospinal fluid increase with age in patients free from neurodegenerative disease," <u>Neuroscience Letters</u> , 172:122-124 (1994). |

| | | | | |
|-----|---|----------|------------|---------------------|
| 168 | VERBEEK et al., "Accumulation of Intercellular Adhesion Molecule-1 in Senile Plaques in Brain Tissue of patients with Alzheimer's Disease," <u>Amer. Journ. Pathology</u> , 144(1):104-116 (1994). | | | |
| 169 | WALKER et al., "Labeling of Cerebral Amyloid <i>In Vivo</i> with a Monoclonal Antibody," <u>J. Neuropath. Exp. Neurology</u> , 53(4):377-383 (1994). | | | |
| 170 | WENGENACK et al., "Targeting Alzheimer amyloid plaques in vivo," <u>Nature Biotech.</u> , 18:868-872 (2000). | | | |
| 171 | WEINER et al., "ORAL TOLERANCE: Immunologic Mechanisms and Treatment of Animal and Human Organ-Specific Autoimmune Diseases by Oral Administration of Autoantigens," <u>Annu. Rev. Immunol.</u> , 12:809-837 (1994). | | | |
| 172 | WEISSMANN et al., "Bovine spongiform encephalopathy and early onset variant Creutzfeldt-Jakob disease," <u>Curr. Opin. Neurobiol.</u> , 7: 695-700 (1997). | | | |
| 173 | WOOD et al., "Amyloid precursor protein processing and A β 42 deposition in a transgenic mouse model of Alzheimer disease," <u>PNAS USA</u> , 94: 1550-1555 (1997). | | | |
| 174 | Human Immunology & Cancer Program brochure, from The University of Tennessee Medical Center/ Graduate School of Medicine, Knoxville, Tennessee (publication date unknown). | | | |
| 175 | 5,441,870 | | 08-15-1995 | Seubert, et al. |
| 176 | BARD et al., "Peripherally administered antibodies against amyloid β -peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease," <u>Nature Medicine</u> , 6(8):916-919 (2000). | | | |
| 177 | HELMUTH, "Further Progress on a β -Amyloid Vaccine," <u>Science</u> , 289:375 (2000). | | | |
| 178 | SCHENK et al., "Therapeutic Approaches Related to Amyloid- β Peptide and Alzheimer's Disease," <u>J. Med. Chem.</u> , 38(21):4141-4154 (1995). | | | |
| 179 | SOUTHWICK et al., "Assessment of Amyloid β protein in Cerebrospinal fluid as an Aid in the Diagnosis of Alzheimer's Disease," <u>J. Neurochemistry</u> , 66:259-265 (1996). | | | |
| 180 | WEN, G.Y., "Alzheimer's Disease and Risk Factors," <u>J. Food Drug Analysis</u> , 6(2):465-476 (1998). | | | |
| 181 | 5,270,165 | | 12-14-1993 | Van Nostrand et al. |
| 182 | HANAN and SOLOMON, "Inhibitory effect of monoclonal antibodies on Alzheimer's β -amyloid peptide aggregation," <u>Int. J. Exp. Clin. Invest.</u> , 3:130-133 (1996). | | | |
| 183 | KATZAV-GOZANSKY et al., "Effect of monoclonal antibodies in preventing carboxypeptidase A aggregation," <u>Biotechnol. Appl. Biochem.</u> , 23:227-230 (1996). | | | |
| 184 | LI and SOLOMON, "Thermal Stabilization of Carboxypeptidase A as a Function of PH and Ionic Milieu," <u>Biochem. Mol. Biol. Int.</u> , 43(3):601-611 (1997). | | | |
| 185 | SOLOMON and et al., "Modulation of The Catalytic Pathway of Carboxypeptidase A by Conjugation with Polyvinyl Alcohols," <u>Adv. Mol. Cell Biology</u> , 15A:33-45 (1996). | | | |
| 186 | SOLOMON et al., "Activity of monoclonal antibodies in prevention of in vitro aggregation of their antigens," abstract from Department of Molecular Microbiology and Biotechnology, Tel Aviv University, Tel Aviv, Israel (publication date unknown). | | | |
| 187 | EP | 783 104 | A1 | 07-09-1997 |
| 188 | WO | 00/43049 | A1 | 07-27-2000 |
| 189 | SAIDO et al., "Spatial Resolution of Fodrin Proteolysis in Postschismic Brain," <u>J. Biol. Chem.</u> , 268(33):25239-25243 (1993). | | | |
| 190 | GRAVINA et al., "Amyloid β Protein (A β) in Alzheimer's Disease," <u>J. Biol. Chem.</u> , 270(13):7013-7016 (1995). | | | |
| 191 | MURPHY et al., "Development of a Monoclonal Antibody Specific for the COOH-Terminal of β -Amyloid 1-42 and Its Immunohistochemical Reactivity in Alzheimer's Disease and Related Disorders," <u>Am. J. Pathology</u> , 144(5):1082-1088 (1994). | | | |

| | | | | |
|-----|---|----|------------|------------------|
| 192 | IWATSUBO et al., "Visualization of A β 42(43) and A β 40 in Senile Plaques with End-Specific A β Monoclonals: Evidence That an Initially Deposited Species Is A β 42(43)," <u>Neuron</u> , 13:45-53 (1994). | | | |
| 193 | HARRINGTON et al., "Characterization of an epitope specific to the neuron-specific isoform of human enolase recognized by a monoclonal antibody raised against a synthetic peptide corresponding to the C-terminus of β / A4-protein," <u>Biochimica Biophysica Acta</u> , 1158:120-128 (1993). | | | |
| 194 | SAIDO et al., "Spatial Resolution of the Primary β -Amyloidogenic Process Induced in Posts ischemic Hippocampus," <u>J. Biol. Chem.</u> , 269(21):15253-15257 (1994). | | | |
| 195 | KONIG et al., "Development and Characterization of a Monoclonal Antibody 369.2B Specific for the Carboxyl-Terminus of the β A4 Peptide," <u>Annals of NY Acad. Sci.</u> , 777:344-355 (1996). | | | |
| 196 | 6,150,091 | | 11-21-2000 | Pandolfo et al. |
| 197 | 5,744,368 | | 04-28-1998 | Goldgaber et al. |
| 198 | 5,004,697 | | 04-20-1991 | Pardridge |
| 199 | WO 00/77178 | A1 | 12-21-2000 | |
| 200 | WO 95/12815 | A1 | 05-11-1995 | |
| 201 | WO 94/28412 | A1 | 12-08-1994 | |
| 202 | WO 97/21728 | A1 | 06-19-1997 | |
| 203 | WO 99/00150 | A2 | 01-07-1999 | |
| 204 | BERCOVICI et al., "Chronic Intravenous Injections of Antigen Induce and Maintain Tolerance in T Cell Receptor-Transgenic Mice," <u>Eur. J. Immunol.</u> , 29:345-354 (1999). | | | |
| 205 | WO 93/04194 | A1 | 03-04-1993 | |
| 206 | MORI et al., "Mass Spectrometry of Purified Amyloid β Protein in Alzheimer's Disease," <u>J. Biol. Chem.</u> , 267(24):17082-17088 (1992). | | | |
| 207 | 5,780,587 | | 07-14-1998 | Potter |
| 208 | WO 96/28471 | A1 | 09-19-1996 | |
| 209 | RUDINGER, "Characteristics of the Amino Acids as Components of a Peptide Hormone Sequence," in <u>Peptide Hormones</u> , J.A. Parson, ed. University Park Press, Baltimore, pp 1-7 (1976). | | | |
| 210 | FRIEDLAND et al., "Development of an anti-A β monoclonal antibody for in vivo imaging of amyloid angiopathy in Alzheimer's disease," <u>Mol. Neurology</u> , 9:107-113 (1994). | | | |
| 211 | 5,736,142 | | 04-07-1998 | Sette et al. |
| 212 | BICKEL et al., "Site Protected, Cationized Monoclonal Antibody Against Beta Amyloid as a Potential Diagnostic Imaging Technique for Alzheimer's Diseases," <u>Soc. for Neuroscience Abstracts</u> , 18:764 (1992). | | | |
| 213 | CHEN et al., "An Antibody to β Amyloid Precursor Protein Inhibits Cell-substratum Adhesion in Many Mammalian Cell Types," <u>Neuroscience Letters</u> , 125:223-226 (1991). | | | |
| 214 | DEMATTOS et al., "Peripheral Anti A β Antibody Alters CNS And Plasma A β Clearance and Decreases Brain A β Burden in a Mouse Model of Alzheimer's Disease," <u>Proc. Natl. Acad. Sci. USA</u> , 10.1073/pnas.151261398 (2001). | | | |
| 215 | GAMES et al., "Prevention and Reduction of AD-type Pathology in PDAPP Mice Immunized with A β ₁₋₄₂ ," <u>Annals of the New York Academy of Science</u> 920:274-84 (2000). | | | |
| 216 | JOACHIM et al., "Antibodies to Non-beta Regions of the Beta-amyloid Precursor Protein Detect a Subset of Senile Plaques," <u>Am. J. of Pathology</u> , 138:373-384 (1991). | | | |
| 217 | MASTERS et al., "Amyloid Plaque core protein in Alzheimer Disease and Down Syndrome," <u>Proc. Natl. Acad. Sci. USA</u> , 82:4245-4249 (1985). | | | |
| 218 | MAJOCHA et al., "Development of a Monoclonal Antibody Specific for β /A4 Amyloid in Alzheimer's Disease Brain for Application to In Vitro Imaging of Amyloid Angiopathy," <u>The J. of Nuclear Med.</u> 33:2184-2189 (1992). | | | |
| 219 | WONG et al., "Neuritic Plaques and Cerebrovascular Amyloid in Alzheimer Disease are Antigenically Related," <u>PNAS USA</u> , 82:8729-8732 (1985). | | | |

| | | | | |
|-----|---|----------|------------|------------------|
| 220 | Dialog/Derwent, Abstract of WPI Acc No: 1997-054436/199706: Stable vaccine compsns. – comprise a macrocyclic lactone, a milbemycin, an avermectin, an antigen, a dispersing agent, an adjuvant, a water sol. organic solvent and saline or water, Derwent File 351: Derwent WPI database. (Publication date unknown.) | | | |
| 221 | 5,989,566 | | 11-23-1999 | Cobb et al. |
| 222 | Chemical Abstract database, Abstract of "Injection of Newborn Mice with Seven Chemical Adjuvants to Help Determine Their Safety in Use in Biologicals," Chemical Abstract database. (Publication date unknown.) | | | |
| 223 | WISCONSIN ALUMNI RESEARCH FOUNDATION, "Injection of Newborn Mice with Seven Chemical Adjuvants to Help Determine Their Safety in Use in Biologicals", U.S. Govt. Res. Develop. Rep., 70(24), 56. (Publication date unknown.) | | | |
| 224 | Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Thimerosal in Vaccines (Mercury in Plasma-Derived Products), web site contents found at : http://www.fda.gov/cber/vaccine/thimerosal.htm , last updated May 16, 2002. | | | |
| 225 | Elan, "Elan and AHP Provide an Update on the Phase 2A Clinical Trial of AN-1792," Press Release. (1/18/2002). | | | |
| 226 | Elan, "Elan and Wyeth Provide Update on Status of Alzheimer's Collaboration," Press Release (3/1/2002) | | | |
| 227 | WO | 95/11008 | A2 | 04-27-1995 |
| 228 | BARROW et al., "Solution Conformations and aggregational Properties of Synthetic Amyloid Beta-Peptides of Alzheimer's Disease. Analysis of Circular Dichroism Spectra," <i>J. Mol.Biol.</i> , 225(4): 1075-1093 (1992). | | | |
| 229 | HAZAMA, et al., "Intranasal Immunization Against Herpes Simplex Virus Infection by Using a Recombinant Glycoprotein D Fused With Immunomodulating Proteins, the B Subunit of Escherichia Coli Heat-Labile Enterotoxin and Interleukin-2", <i>Immunology</i> , Vol. 78: 643-649 (1993). | | | |
| 230 | 6,262,335 | B1 | 07-17-2001 | Hsiao et al. |
| 231 | 6,114,133 | | 09-05-2000 | Seubert et al. |
| 232 | PETERSON, et al., "Recombinant Antibodies: Alternative Strategies for Developing and Manipulating Murine-Derived Monoclonal Antibodies," <i>Laboratory Animal Science</i> , 46(1):8-14 (1996). | | | |
| 233 | MORRIS, et al., "The Consortium to Establish a registry for Alzheimer's Disease (CERAD)," <i>Neurology</i> , 39:1159-65 (1989). | | | |
| 234 | 6,284,221 | B1 | 09-04-2001 | Schenk, et al. |
| 235 | NEWCOMBE and COHEN, "Solubility characteristics of isolated amyloid fibrils," <i>Biochim. Biophys. Acta</i> , 104:480-486 (1965). | | | |
| 236 | HILBICH et al., "Human and rodent sequence analogs of Alzheimer's amyloid β A4 share similar properties and can be solubilized in buffers of pH 7.4," <i>Eur. J. Biochem.</i> , 201:61-69 (1991). | | | |
| 237 | GORTNER, <i>Outlines of Biochemistry</i> , pp. 322-323, John Wiley & Sons, Inc., New York (1949). | | | |
| 238 | MCNEAL et al., "Stimulation of local immunity and protection in mice by intramuscular immunization with triple- or double-layered rotavirus particles and QS-21," <i>Virology</i> , 243:158-166 (1998). | | | |
| 239 | BEASLEY, "Alzheimer's traced to proteins caused by aging," Reuters, April 20, 2001 7:56 PM ET. | | | |
| 240 | WO | 00/43039 | A1 | 07-27-2000 |
| 241 | HAASS et al. "Amyloid beta-peptide is produced by cultured cells during normal metabolism," <i>Nature</i> , 359(6393):322-5 (1992). | | | |
| 242 | 60/168,594 | | 11-29-1999 | Chalifour et al. |
| 243 | WO | 01/39796 | A2 | 06-07-2001 |
| 244 | FRENKEL, et al., "Modulation of Alzheimer's β -amyloid neurotoxicity by site-directed single chain antibody," <i>J. of Neuroimmunology</i> , 106:23-31 (2000). | | | |
| 245 | FRENKEL et al., "High affinity binding of monoclonal antibodies to the sequential epitope EFRH of β -amyloid peptide is essential for modulation of fibrillar aggregation," <i>J. of Neuroimmunology</i> , 95:136-142 (1999). | | | |

| | |
|-----|---|
| 246 | FRENKEL et al., "Generation of auto-antibodies towards Alzheimer's disease vaccination," <u>Vaccine</u> , 19:2615-2619 (2001). |
| 247 | FRENKEL et al., "Immunization against Alzheimer's β -amyloid plaques via EFRH phage administration," <u>PNAS USA</u> , 97:11455-11459 (2000). |
| 248 | FRENKEL et al., "N-terminal EFRH sequence of Alzheimer's β -amyloid peptide represents the epitope of its anti-aggregating antibodies," <u>J. of Neuroimmunology</u> , 88:85-90 (1998). |
| 249 | FRIEDLAND, et al., "Neuroimaging of Vessel Amyloid in Alzheimer's Disease," in <u>Cerebrovascular Pathology in Alzheimer's Disease</u> , eds. de la Torre and Hachinski, New York Academy of Sciences, New York, New York (1997). |
| 250 | NAKAMURA et al., "Histopathological studies on senile plaques and cerebral amyloid angiopathy in aged cynomolgus monkeys," <u>Exp. Anim.</u> , 43:711-718 (1995). |
| 251 | GARDELLA et al., "Intact Alzheimer amyloid precursor protein (APP) is present in platelet membranes and is encoded by platelet mRNA," <u>Biochem. Biophys. Res. Comm.</u> , 173:1292-1298 (1990). |
| 252 | GEDDES, "N-terminus truncated β -amyloid peptides and C-terminus truncated secreted forms of amyloid precursor protein: distinct roles in the pathogenesis of Alzheimer's disease," <u>Neurobiology of Aging</u> , 20:75-79 (1999). |
| 253 | GIULIAN, et al., "The HHQK Domain of b-Amyloid Provides a Structural Basis for the Immunopathology of Alzheimer's Disease," <u>Journal of Biological Chem.</u> , 273:29719-29726 (1998). |
| 254 | GRUBECK-LOEBENSTEIN, et al., "Immunization with β -amyloid: could T-cell activation have a harmful effect?," <u>TINS</u> , 23:114 (2000). |
| 255 | HARIGAYA, et al., "Modified amyloid β protein ending at 42 or 40 with different solubility accumulates in the brain of Alzheimer's disease," <u>Biochem. Biophys. Res. Comm.</u> , 211:1015-1022 (1995). |
| 256 | IKEDA, et al., "Immunogold labeling of cerebrovascular and neuritic plaque amyloid fibrils in Alzheimer's disease with an anti- β protein monoclonal antibody," <u>Lab. Invest.</u> , 57:446-449 (1987). |
| 257 | JEN, et al., "Preparation and purification of antisera against different regions or isoforms of b-amyloid precursor protein," <u>Brain Research Protocols</u> , 2:23-30 (1997). |
| 258 | KIDA, et al., "Early amyloid- β deposits show different immunoreactivity to the amino- and carboxy-terminal regions of b-peptide in Alzheimer's disease and Down's syndrome brain," <u>Neuroscience Letters</u> , 193:105-108 (1995). |
| 259 | LANSBURY, PETER T., "Inhibition of amyloid formation: a strategy to delay the onset of Alzheimer's disease," <u>Curr. Ops. in Chemical Biology</u> , 1:260-267 (1997). |
| 260 | LEMERE, et al., "Nasal A β treatment induces anti-A β antibody production and decreases cerebral amyloid burden in PD-APP mice," <u>Annals of the NY Acad. Sci.</u> , 920:328-331 (2000). |
| 261 | MAK, et al., "Polyclonals to b-amyloid (1-42) identify most plaque and vascular deposits in Alzheimer cortex, but not striatum," <u>Brain Research</u> , 667:138-142 (1994). |
| 262 | MANN, et al., "The extent of amyloid deposition in brain in patients with Down's syndrome does not depend upon the apolipoprotein E genotype," <u>Neuroscience Letters</u> , 196:105-108 (1995). |
| 263 | MANN, et al., "Amyloid β protein (A β) deposition in chromosome 14-linked Alzheimer's disease: Predominance of A β ₄₂₍₄₃₎ ," <u>Annals of Neurology</u> , 40:149-156 (1996). |
| 264 | MCGEER, et al., "Immunohistochemical localization of beta-amyloid precursor protein sequences in Alzheimer and normal brain tissue by light and electron microscopy," <u>J. of Neuroscience Res.</u> , 31:428-442 (1992). |
| 265 | MENA, et al., "Monitoring pathological assembly of tau and β -amyloid proteins in Alzheimer's disease," <u>Acta Neuropathol.</u> , 89:50-56 (1995). |

| | | | | |
|-----|--|--|------------|----------------|
| 266 | CHAPMAN, "Model behavior," <u>Nature</u> , 408:915-916 (2000). | | | |
| 267 | 6,294,171 B2 | | 09-25-2001 | McMichael |
| 268 | NAKAMURA, et al., "Carboxyl end-specific monoclonal antibodies to amyloid β protein ($A\beta$) subtypes ($A\beta$ 40 and $A\beta$ 42(43) differentiate Ab in senile plaques and amyloid angiopathy in brains of aged cynomolgus monkeys," <u>Neuroscience Letters</u> , 201:151-154 (1995). | | | |
| 269 | PHILIPPE, et al. "Generation of a monoclonal antibody to the carboxy-terminal domain of tau by immunization with the amino-terminal domain of the amyloid precursor protein," <u>J. of Neuroscience Res.</u> , 46:709-719 (1996). | | | |
| 270 | SCHENK, et al., " β -peptide immunization," <u>Arch. Neurol.</u> , 57:934-936 (2000). | | | |
| 271 | ST. GEORGE-HYSLOP et al., "Antibody clears senile plaques," <u>Nature</u> , 40:116-117 (1999). | | | |
| 272 | SZENDREI, et al., "The effects of aspartic acid-bond isomerization on in vitro properties of the amyloid β -peptide as modeled with N-terminal decapeptide fragments," <u>Int. J. Peptide Protein Res.</u> , 47:289-296 (1996). | | | |
| 273 | THORSETT, E.D. et al., "Therapeutic approaches to Alzheimer's disease," <u>Curr. Op. in Chem. Biology</u> , 4:377-382 (2000). | | | |
| 274 | WEINER et al., "Nasal administration of amyloid- β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease," <u>Annals of Neurology</u> , 48:567-579 (2000). | | | |
| 275 | WU, et al., "Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor," <u>J. Clin. Invest.</u> , 100:1804-1812 (1997). | | | |
| 276 | TJERNBERG et al., "Arrest of β -amyloid fibril formation by a pentapeptide ligand," <u>Journal of Biological Chemistry</u> , 271:8545-8548 (1996). | | | |
| 277 | SASAKI et al., "Human choroid plexus is an uniquely involved area of the brain in amyloidosis: a histochemical, immunohistochemical and ultrastructural study," <u>Brain Res.</u> , 755:193-201 (1997). | | | |
| 278 | SAITOH, N. et al., "Immunological analysis of Alzheimer's disease using anti- β -protein monoclonal antibodies," <u>Sapporo Med. J.</u> , 60:309-320 (1991). | | | |
| 279 | SAITO et al., "Vector-mediated delivery of 125 I-labeled β -amyloid peptide Ab $^{1-40}$ through the blood-brain barrier and binding to Alzheimer disease amyloid of the $A\beta^{1-40}$ vector complex," <u>PNAS USA</u> , 92:10227-10231 (1995).** | | | |
| 280 | PARDRIDGE et al., "Chimeric peptides as a vehicle for peptide pharmaceutical delivery through the blood-brain barrier," <u>Biochem. Biophys. Res. Comm.</u> , 146:307-313 (1987). | | | |
| 281 | NAKAYAMA et al., "Histopathological studies of senile plaques and cerebral amyloidosis in cynomolgus monkeys," <u>J. of Med. Primatology</u> , 27:244-252 (1998). | | | |
| 282 | 60/169,687 | | 12-08-1999 | Chain |
| 283 | 09/441,140 | | 11-16-1999 | Solomon et al. |
| 284 | 5,231,170 | | 07-27-1993 | Averback |
| 285 | CAPUTO et al., "Therapeutic approaches targeted at the amyloid proteins in Alzheimer's disease," <u>Clin. Neuropharm.</u> , 15:414A-414B (1992). | | | |
| 286 | CORDELL, B., " β -Amyloid formation as a potential therapeutic target for Alzheimer's disease," <u>Ann. Rev. Pharmacol. Toxicol.</u> , 34:69-89 (1994). | | | |
| 287 | COSTA et al., "Immunoassay for transthyretin variants associated with amyloid neuropathy," <u>Scand. J. Immunol.</u> , 38:177-182 (1993). | | | |
| 288 | DUMERY et al., " β -Amyloid protein aggregation: its implication in the physiopathology of Alzheimer's disease," <u>Pathol. Biol.</u> , 49:72-85 (2001). | | | |
| 289 | ESIRI, "Is an effective immune intervention for Alzheimer's disease in prospect?," <u>Trends in Pharm. Sci.</u> , 22:2-3 (2001). | | | |

| | | | | |
|-----|---|-----------------|----|------------|
| 290 | YOUNKIN, "Amyloid β vaccination: reduced plaques and improved cognition," <u>Nature Medicine</u> , 7:18-19 (2001). | | | |
| 291 | COLOMA et al., "Transport Across the Primate Blood-Brain Barrier of a Genetically Engineered Chimeric Monoclonal Antibody to the Human Insulin Receptor," <u>Pharm. Res.</u> , 17:266-274 (2000). | | | |
| 292 | YAMAGUCHI et al., Diffuse plaques associated with astroglial amyloid β protein, possibly showing a disappearing stage of senile plaques," <u>Acta Neuropathol.</u> , 95:217-222 (1998). | | | |
| 293 | DALY, et al., "Detection of the membrane-retained carboxy-terminal tail containing polypeptides of the amyloid precursor protein in tissue from Alzheimer's Disease brain," <u>Life Sci.</u> , 63:2121-2131 (1998). | | | |
| 294 | WO | 01/62801 | A2 | 08-30-2001 |
| 295 | | 60/184,601 | | 02-24-2000 |
| 296 | | 60/254,465 | | 12-08-2000 |
| 297 | | 60/254,498 | | 12-08-2000 |
| 298 | WO | 01/42306 | A2 | 06-14-2001 |
| 299 | | 60/186,295 | | 03-01-2000 |
| 300 | | 2001/0018053 A1 | | 08-30-2001 |
| 301 | WO | 01/62284 | A2 | 03-01-2000 |
| 302 | CHUNG et al., "Uptake, Degradation, and Release of Fibrillar and Soluble Forms of Alzheimer's Amyloid β -Peptide by Microglial Cells," <u>J. Biol. Chem.</u> , 274(45):32301-32308 (1999). | | | |
| 303 | GONZALES-FERNANDEZ et al., "Low antigen dose favors selection of somatic mutants with hallmarks of antibody affinity maturation," <u>Immunology</u> , 93:149-153 (1998). | | | |
| 304 | RASO, V.A., Grant application # 1 R43 AGI 5746-01 (non-redacted version), "Immunotherapy of Alzheimer's Disease" (publication date unknown). | | | |
| 305 | | 09/724,842 | | 11-28-2000 |
| 306 | | 6,417,178 | B1 | 07-09-2002 |
| 307 | CHEN et al., "A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease," <u>Nature</u> , 408(6815):975-9 (2000). | | | |
| 308 | JANUS et al., "A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease," <u>Nature</u> , 408(6815):979-82 (2000). | | | |
| 309 | MATTSON, Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. <u>Physiol Rev.</u> 77(4):1081-132 (1997). | | | |
| 310 | MERLUZZI, et al., "Humanized antibodies as potential drugs for therapeutic use," <u>Adv Clin Path.</u> , 4(2):77-85 (2000). | | | |
| 311 | MORGAN, et al., "A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease," <u>Nature</u> . 408(6815):982-5 (2000). | | | |
| 312 | SCHENK, et al., "Immunotherapy with beta-amyloid for Alzheimer's disease: a new frontier," <u>DNA Cell Biol.</u> , 20(11):679-81 (2001). | | | |
| 313 | SELKOE, "The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease," <u>Trends Cell Biol.</u> , 8(11):447-53 (1998). | | | |
| 314 | SIGURDSSON, et al., "In vivo reversal of amyloid-beta lesions in rat brain," <u>J Neuropathol Exp Neurol.</u> , 59(1):11-17 (2000). | | | |
| 315 | SINHA, et al., "Recent advances in the understanding of the processing of APP to beta amyloid peptide," <u>Ann N Y Acad Sci.</u> , 920:206-8 (2000). | | | |
| 316 | SOTO, et al. Beta sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. <u>Nat Med.</u> 4(7):822-6 (1998). | | | |

| | | | | | |
|-----|--|--------|------------|---------------|--|
| 317 | VEHMAS, et al. beta-Amyloid peptide vaccination results in marked changes in serum and brain Abeta levels in APPswe/PS1 DeltaE9 mice, as detected by SELDI-TOF-based ProteinChip® technology. <i>DNA Cell Biol.</i> (11):713-21 (2001). | | | | |
| 318 | DU et al., "Reduced levels of amyloid beta-peptide antibody in Alzheimer disease," <i>Neurology</i> , 57(5):801-5 (2001). | | | | |
| 319 | SMALL, et al. Alzheimer's disease and Abeta toxicity: from top to bottom. <i>Nat Rev Neurosci.</i> 2(8):595-8 (2001). | | | | |
| 320 | 5,593,846 | | 01-14-1997 | Schenk et al. | |
| 321 | 5,837,672 | | 11-17-1998 | Schenk et al. | |
| 322 | WO 00/72880 | A2, A3 | 12-07-2000 | | |
| 323 | WO 00/72876 | A2, A3 | 12-07-2000 | | |
| 324 | WO 00/72870 | A1 | 12-07-2000 | | |
| 325 | 2001/0102261 | A1 | 08-01-2002 | Raso | |
| 326 | 2002/0136718 | A1 | 09-26-2002 | Raso | |
| 327 | CAMERON, "Recent Advances in Transgenic Technology," <i>Molecular Biotechnology</i> , 7:253-265 (1997). | | | | |
| 328 | FELSENSTEIN et al., "Transgenic Rat and In-Vitro Studies of B-Amyloid Precursor Protein Processing;" <i>Alzheimer's and Parkinson's Diseases</i> , Hanin et al. Ed., pp 401-409, Plenum Press, New York, (1995). | | | | |
| 329 | NIEMANN, "Transgenic farm animals get off the ground;" <i>Transgenic Research</i> 7:73-75 (1998). | | | | |
| 330 | SIGMUND, "Viewpoint: Are Studies in Genetically Altered Mice Out of Control," <i>Arterioscler Thromb Vasc Biol.</i> , 20:1425-1429 (2000). | | | | |
| 331 | WO 99/06545 | A2 | 11-02-1999 | | |
| 332 | CHEN et al., "Neurodegenerative Alzheimer-like pathology in PDAPP 717V→F transgenic mice," <i>Progress in Brain Research</i> , Van Leeuwen et al. Eds, 117:327-337 (1998). | | | | |
| 333 | CONWAY et al., "Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy," <i>PNAS</i> , 97(2):571-576 (2000) | | | | |
| 334 | JOBLING and HOLMES, "Analysis of structure and function of the B subunit of cholera toxin by the use of site-directed mutagenesis," <i>Molecular Microbiology</i> , 5(7):1755-1767 (1991). | | | | |
| 335 | MASLIAH et al., "β-Amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease," <i>PNAS</i> , 98(21):12245-12250 (2001). | | | | |
| 336 | PERUTZ et al., "Amyloid fibers are water-filled nanotubes," <i>PNAS</i> , 99(8):5591-5595 (2002). | | | | |
| 337 | SKOLNICK and FETROW, "From genes to protein structure and function: novel applications of computational approaches in the genomic era," <i>Trends in Biotech.</i> , 18(1):34-39 (2000). | | | | |
| 338 | STEIN et al., "Lack of Neurodegeneration in Transgenic Mice Overexpressing Mutant Amyloid Precursor Protein is Associated with Increased Levels of Transthyretin and Activation of Cell Survival Pathways," <i>The Journal of Neuroscience</i> , 22(17):7380-7388 (September 1, 2002). | | | | |
| 339 | TENNENT et al., "Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer's disease and systemic amyloidosis," <i>PNAS</i> , 92:4299-4303 (1995). | | | | |


Applicant believes that no fee is required for submission of this statement.

However, if a fee is required, the Commissioner is authorized to deduct such fee from the

Schenk et al.
Application No.: 09/580,018

undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Rosemarie L. Celli". The signature is fluid and cursive, with the first name being the most prominent.

Rosemarie L. Celli
Reg. No. 42,397

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 650-326-2400
Fax: 650-326-2422
RLC:rlc
60023695 v1